Soligenix Inc
SNGX1.130USD
+0.090+8.65%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
11.14MValor de mercado
PerdaP/L TTM
Mais detalhes de Soligenix Inc Empresa
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Informações de Soligenix Inc
Código da empresaSNGX
Nome da EmpresaSoligenix Inc
Data de listagemApr 04, 1994
CEOSchaber (Christopher J)
Número de funcionários14
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 04
Endereço29 Emmons Drive
CidadePRINCETON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal08540
Telefone16095388200
Sitehttps://www.soligenix.com/
Código da empresaSNGX
Data de listagemApr 04, 1994
CEOSchaber (Christopher J)
Executivos da empresa Soligenix Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
15.51K
+15132.00%
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Oreola Donini, Ph.D.
Dr. Oreola Donini, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Jonathan L. Guarino, CPA
Mr. Jonathan L. Guarino, CPA
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
15.51K
+15132.00%
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Oreola Donini, Ph.D.
Dr. Oreola Donini, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sex, 5 de dez
Atualizado em: sex, 5 de dez
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Armistice Capital LLC
7.02%
Intracoastal Capital, L.L.C.
4.21%
DRW Securities, LLC
1.70%
Two Sigma Investments, LP
0.87%
The Vanguard Group, Inc.
0.85%
Outro
85.35%
Investidores
Investidores
Proporção
Armistice Capital LLC
7.02%
Intracoastal Capital, L.L.C.
4.21%
DRW Securities, LLC
1.70%
Two Sigma Investments, LP
0.87%
The Vanguard Group, Inc.
0.85%
Outro
85.35%
Tipos de investidores
Investidores
Proporção
Hedge Fund
8.66%
Corporation
4.21%
Investment Advisor
3.92%
Investment Advisor/Hedge Fund
1.35%
Research Firm
0.51%
Individual Investor
0.16%
Outro
81.19%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
45
1.46M
14.44%
+1.17M
2025Q3
42
242.17K
2.89%
-108.56K
2025Q2
50
150.04K
4.60%
-125.61K
2025Q1
50
149.55K
4.59%
-122.83K
2024Q4
62
34.48K
1.37%
-224.66K
2024Q3
62
66.84K
2.91%
-140.04K
2024Q2
61
101.18K
6.59%
-9.86K
2024Q1
57
15.87K
2.48%
-90.98K
2023Q4
55
24.60K
3.87%
-67.56K
2023Q3
57
57.20K
9.40%
-37.02K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Armistice Capital LLC
708.00K
7.02%
+708.00K
--
Sep 30, 2025
Intracoastal Capital, L.L.C.
425.00K
4.21%
+425.00K
--
Sep 25, 2025
DRW Securities, LLC
171.42K
1.7%
+171.42K
--
Sep 30, 2025
Two Sigma Investments, LP
87.65K
0.87%
+87.65K
--
Sep 30, 2025
The Vanguard Group, Inc.
52.52K
0.52%
+50.34K
+2303.75%
Sep 30, 2025
Sabby Management, LLC
81.00K
0.8%
+81.00K
--
Sep 30, 2025
Renaissance Technologies LLC
72.90K
0.72%
+72.90K
--
Sep 30, 2025
HRT Financial LP
54.67K
0.54%
+54.67K
--
Sep 30, 2025
Virtu Americas LLC
50.86K
0.5%
+50.86K
--
Sep 30, 2025
Banco BTG Pactual SA
46.37K
0.46%
+46.37K
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
Data
Data ex-dividendo
Tipo
Proporção
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
